Contact: Allison Hydzik
University of Pittsburgh Schools of the Health Sciences
Caption: University of Pittsburgh Cancer Institute researchers screened 89 FDA-approved cancer drugs to see if any of them would be effective against a rare type of tumor. Surprisingly, 37 of the drugs, or 41.5 percent, exhibited promising activity against the tumor in laboratory tests, with two identified as candidates for future clinical trials. The brighter colors indicate anti-cancer activity.
Usage Restrictions: Credit required
Related news release: Laboratory detective work points to potential therapy for rare, drug-resistant cancer